Into the unknown: How quickly can vaccines be developed for Disease X
A flesh-eating fungus; a blood-borne bacteria transmitted by horse flies; or perhaps a virus that’s more contagious than SARS-CoV-2? These…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a trainee reporter for Medical Device Network, covering developments in the healthcare sector. Coming from a scientific and medical background, Robert has reported across various topics with expertise in neuroscience, genetics, and epidemiology. Previously, he worked on a freelance basis with New Scientist.
-
-
Bavarian Nordic promises two million mpox vaccines for Africa by end of 2024
Bavarian Nordic will prioritise the production of two million mpox vaccines by the end of this year to help fight…
-
Teva agrees to pay Baltimore City $80m for fuelling opioid epidemic
Teva Pharmaceuticals has reached an $80m settlement with the city of Baltimore for its role in worsening the opioid epidemic,…
-
Immunovant touts positive Phase II batoclimab data as IMVT-1402 also progresses
Immunovant has reported positive results from a trial investigating its monoclonal antibody drug batoclimab in Graves’ disease patients, as its…
-
GSK’s asthma blockbuster Nucala secures win in COPD Phase III trial
GSK’s asthma drug Nucala (mepolizumab) has met the primary endpoint in a Phase III trial treating patients with chronic obstructive…
-
eGenesis scoops $191m for genetically modified pig kidney transplant trial
Investors are rallying around the promise of cross-species transplantation, enabling eGenesis to close a $191m Series D financing round to…
-
Actimed’s ALS candidate wins FDA orphan drug designation
The US Food and Drug Administration (FDA) has granted an orphan drug designation to Actimed Therapeutics’ S-oxprenolol (ACM-002) for the…
-
Ocaliva approval in Europe withdrawn following data re-assessment
Advanz Pharma said it is “considering all options” after the European Commission (EC) revoked Ocaliva’s (obeticholic acid) conditional marketing authorisation.…
-
Repare Therapeutics cuts quarter of its workforce and prioritises clinical assets
Repare Therapeutics plans to reduce its workforce by around 25% as the company prioritises operations on its four clinical programmes…
-
Singapore approves mpox vaccine as it adds border infection checks
Nearly a week after confirming it has detected 13 cases of mpox in 2024, Singapore has approved Bavarian Nordic’s Jynneos…